Acute leukemias with ETV6/ABL1 (TEL/ABL) Fusion: Poor prognosis and prenatal origin

Genes Chromosomes and Cancer

Volumn 49, Issue 10, 2010, Pages 873-884

  Zuna, Jan ^a   Zaliova, Marketa ^a   Muzikova, Katerina ^a   Meyer, Claus ^b   Lizcova, Libuse ^c   Zemanova, Zuzana ^c   Brezinova, Jana ^d   Votava, Felix ^e   Marschalek, Rolf ^b   Stary, Jan ^a   Trka, Jan ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b GOETHE UNIVERSITY   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHILD; CLINICAL ASSESSMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE MARKER; DNA EXTRACTION; EOSINOPHILIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENETIC SCREENING; HUMAN; INFANT; LATENT PERIOD; LEUKOCYTOSIS; LYMPHOBLAST; MALE; MINIMAL RESIDUAL DISEASE; ONSET AGE; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADULT; CHILD; CHILD, PRESCHOOL; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT, NEWBORN; MALE; NEONATAL SCREENING; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77957880306     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20796     Document Type: Article

References (42)

1. Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, Hoglund M. 1997. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 20:299-304.
2. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A. 2009. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group. J Clin Oncol 27:377-384.
3. Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG, Nijmeijer BA. 2008. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet 185:37-42.
4. Barbouti A, Ahlgren T, Johansson B, Hoglund M, Lassen C, Turesson I, Mitelman F, Fioretos T. 2003. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol 122:85-93.
5. Brunel V, Sainty D, Carbuccia N, Mozziconacci M, Fernandez F, Simonetti J, Gabert J, Dubreuil P, Lafage-Pochitaloff M, Birg F. 1996. A TEL/ABL fusion gene on chromosome 12p13 in a case of Ph-, BCR-atypical CML. Leukemia 10:2003.
6. Burjanivova T, Madzo J, Muzikova K, Meyer C, Schneider B, Votava F, Marschalek R, Stary J, Trka J, Zuna J. 2006. Prenatal origin of childhood AML occurs less frequently than in child-hood ALL. BMC Cancer 6:100.
7. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ. 1997. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-4952.
8. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. 1998. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 95:4584-4588.
9. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, Greaves M. 1993. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363:358-360.
10. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. 2003. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 17:2318-2357.
11. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, Greaves MF. 1997. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94:13950-13954.
12. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG. 1996. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16:4107-4116.
13. Greaves MF, Wiemels J. 2003. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 3:639-649.
14. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
15. ISCN. 1995. An International System for Human Cytogenetic Nomenclature. In: Mitelman F, editor. S. Karger, Basel: ISCN.
16. Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S. 2008. Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer 47:919-921.
17. Kelly JC, Shahbazi N, Scheerle J, Jahn J, Suchen S, Christacos NC, Mowrey PN, Witt MH, Hostetter A, Meloni-Ehrig AM. 2009. Insertion (12;9)(p13;q34q34): A cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet 192:36-39.
18. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M. 2002. Chronic myelocytic leukemia with eosinophilia, t(9;12) (q34;p13), and ETV6-ABL gene rearrangement: Case report and review of the literature. Cancer Genet Cytogenet 138:139-142.
19. La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, Martelli M, Flandrin G, Pelicci PG, Mecucci C. 2002. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 87:789-794.
20. Lin H, Guo JQ, Andreeff M, Arlinghaus RB. 2002. Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 16:294-297.
21. Malinge S, Monni R, Bernard O, Penard-Lacronique V. 2006. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 25:3589-3597.
22. Meyer-Monard S, Muhlematter D, Streit A, Chase AJ, Gratwohl A, Cross NC, Jotterand M, Tichelli A. 2005. Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia 19:1096-1099.
23. Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. 2004. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 24:4685-4695.
24. Mozziconacci MJ, Sainty D, Chabannon C. 2007. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome. Am J Hematol 82:688-689.
25. Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E. 2009. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: Efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 33:1144-1146.
26. O'Brien SG, Vieira SA, Connors S, Bown N, Chang J, Capdeville R, Melo JV. 2002. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood 99:3465-3467.
27. Okuda K, Golub TR, Gilliland DG, Griffin JD. 1996. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 13:1147-1152.
28. Okuda K, Weisberg E, Gilliland DG, Griffin JD. 2001. ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448.
29. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. 1995. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 55:34-38.
30. Pecquet C, Nyga R, Penard-Lacronique V, Smithgall TE, Murakami H, Regnier A, Lassoued K, Gouilleux F. 2007. The Src tyrosine kinase Hck is required for Tel-Abl-but not for Tel-Jak2-induced cell transformation. Oncogene 26:1577-1585.
31. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J. 2007. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 48:93-100.
32. Tirado CA, Sebastian S, Moore JO, Gong JZ, Goodman BK. 2005. Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet 157:74-77.
33. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ. 2007. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604-611.
34. Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grumayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ. 2009. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 23:1073-1079.
35. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. 1999. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 13:1901-1928.
36. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B, Van Roy N, Marynen P, De Paepe A, Slater R, Speleman F. 2001. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 30:274-282.
37. Voss J, Posern G, Hannemann JR, Wiedemann LM, Turhan AG, Poirel H, Bernard OA, Adermann K, Kardinal C, Feller SM. 2000. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intra-cellular signalling pathways. Oncogene 19:1684-1690.
38. Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM, Smith MT, Zhang L, Feusner J, Wiencke J, Pritchard-Jones K, Kempski H, Greaves M. 2002. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 99:3801-3805.
39. Zaliova M, Fronkova E, Krejcikova K, Muzikova K, Mejstrikova E, Stary J, Trka J, Zuna J. 2009. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: Implications for residual disease monitoring. Leukemia 23:944-951.
40. Zuna J, Ford AM, Peham M, Patel N, Saha V, Eckert C, Kochling J, Panzer-Grumayer R, Trka J, Greaves M. 2004. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res 10:5355-5360.
41. Zuna J, Muzikova K, Ford AM, Maia AT, Krejci O, Tousovska K, Oravkinova I, Greaves M, Trka J. 2003. Prenatal, clonal origin of acute lymphoblastic leukaemia in triplets. Leuk. Lymphoma 44:2099-2102.
42. Zuna J, Prouzova Z, Kalina T, Lizcova L, Zemanova Z, Muzikova K, Rahmatova S, Meijerink JP, Trka J. 2009. Backtracking of ALL to cord blood. Leuk Res 33:e107-108.